Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men
Abstract Non-alcoholic steatohepatitis (NASH) is the most rapidly growing liver disease that is nevertheless without approved pharmacological treatment. Despite great effort in developing novel NASH therapeutics, many have failed in clinical trials. This has raised questions on the adequacy of precl...
Guardado en:
Autores principales: | Anita M. van den Hoek, Lars Verschuren, Martien P. M. Caspers, Nicole Worms, Aswin L. Menke, Hans M. G. Princen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b01d71c202e84e7d903bdef458f54ea0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol.
por: Susan Kühnast, et al.
Publicado: (2013) -
Both transient and continuous corticosterone excess inhibit atherosclerotic plaque formation in APOE*3-leiden.CETP mice.
por: Hanna E Auvinen, et al.
Publicado: (2013) -
Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of Erysipelotrichales.
por: James K Carter, et al.
Publicado: (2021) -
Mechanism-Based Biomarker Prediction for Low-Grade Inflammation in Liver and Adipose Tissue
por: Jolanda H. M. van Bilsen, et al.
Publicado: (2021) -
Estimating Drug Efficacy with a Diet-Induced NASH Model in Chimeric Mice with Humanized Livers
por: Keishi Kisoh, et al.
Publicado: (2021)